Press releases

· Dosing of first patient expected 2Q 2024
· CTA approval marks progress in development of uTRACE[®] in prostate cancer under the collaboration between Curasight and Curium Inc.
· Phase 2 trial is part of Curasight’s efforts to build a pipeline of products using radiopharmaceuticals for improved diagnosis and more targeted treatment of different cancer types
 

Copenhagen, April 16, 2024 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS), a clinical stage radiopharmaceuticals company, today announced approval of clinical trial application (CTA) from the European Medicines Agency (EMA) for the investigation of uTRACE[®] in a phase 2 trial as a non-invasive alternative or supplement to traditional biopsies in prostate cancer patients in active surveillance.

Copenhagen, April 12, 2024 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS)  announces that the chairperson of the Board of Directors, Per Falholt, has today announced that he wishes to step down from the Board of Directors with immediate effect. Kirsten Drejer has been elected as the new chairperson of the Board of Directors.

Copenhagen, Denmark, 21 March 2024 – today Curasight A/S ("Curasight" or the “Company" – TICKER: CURAS) held its Annual General Meeting at the office of DLA Piper Denmark, Oslo Plads 2, 2100 Copenhagen OE, Denmark

Copenhagen, Denmark, 11 March 2024 – Curasight A/S ("Curasight" or the “Company" – TICKER: CURAS) announces today it will not proceed with the Rights Issue announced on February 13[th] 2024 (“Rights Issue”). The Board of Directors took the decision following a less than optimal participation in the Rights Issue by shareholders due to the current challenging market conditions and the fact that Curasight’s share price is trading below the offer price in the Rights Issue. The Company remains committed to accelerating its therapeutic strategy and is currently evaluating alternative financing options.

The Board of Directors is pleased to invite shareholders to the Annual General Meeting of Curasight A/S (“Curasight” or the “Company” – TICKER: CURAS) on

Thursday 21 March 2024 at 10:00 AM (CET) at the office of DLA Piper Denmark, Oslo Plads 2, 2100 Copenhagen OE, Denmark.

Copenhagen, Denmark, 23 February 2024 - Today is the first day of the subscription period in Curasight A/S’s ("Curasight" or the “Company" – TICKER: CURAS) new issue of shares with preferential rights for the Company's existing shareholders of up to DKK 51.2 million before transaction costs (the “Rights Issue"), which was resolved by the Board of Directors on 13 February 2024.

Copenhagen, Denmark, 22 February 2024 - Curasight A/S ("Curasight" or the “Company" – TICKER: CURAS) has prepared and published an information memorandum (the “Information Memorandum”) relating to the new issue of shares with preferential rights for the Company's existing shareholders of up to DKK 51.2 million before transaction costs (the “Rights Issue"), which was resolved by the Board of Directors on 13 February 2024. The Information Memorandum is available on the Company's, Nordic Issuing AB's and Redeye AB's respective websites (www.curasight.com, www.nordic-issuing.se, www.redeye.se).

Copenhagen, Denmark, 22 February 2024 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) hereby publishes the Annual Report for the fiscal year of 2023. The Annual Report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.

Business Highlights during the fourth quarter 2023

· Encouraging preclinical data using uTREAT in non-small cell lung cancer
· Announcing the submission of the clinical trial application to the European Medicines Agency for the investigation of uTRACE in a phase 2 trial
· Advancing the theranostics by ongoing momentum in development pipeline with data and regulatory progress

Copenhagen, Denmark, 22 February 2024 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) hereby publishes the the Year-end report October – December 31, 2023. The Year-end report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.

Copenhagen, Denmark, 13 February 2024 - Curasight A/S ("Curasight" or the “Company" – TICKER: CURAS) has today resolved on a new issue of shares with preferential rights for the Company's existing shareholders of up to DKK 51.2 million before transaction costs (the “Rights Issue"). The proceeds are intended to be used to strengthen the Company’s capital structure and secure funding for the acceleration of clinical activities, including the preparation, planning and enrolment of the first patients in a therapy phase I/IIa basket trial in various cancer types, as well as to strengthen Curasight’s pipeline through preclinical development of new peptide-based radioligands.